BioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution
DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.